May 29, 2025
Source: drugdu
87
On May 28, Kangtai Biological issued an announcement that it received an acceptance notice issued by the National Medical Products Administration today, agreeing to accept the trivalent influenza vaccine jointly developed by the company and Lanzhou Bailing Biotechnology Co., Ltd.Clinical trial application for viral split vaccine (MDCK cells).
The vaccine is suitable for people aged 3 years and above and is intended to stimulate the body to produce immunity against influenza viruses to prevent influenza caused by related types of influenza viruses.
In the first quarter of 2025, Kangtai Biological achieved revenue of 645 million yuan and net profit attributable to shareholders of the parent company of 22.43 million yuan.
网址:https://finance.eastmoney.com/a/202505283416827087.html
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.